Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

Sponsor
Nanjing First Hospital, Nanjing Medical University
Study ID
NCT05990374
Status
Unknown

Conditions

  • Diabetes

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The efficacy of long-term treatment with different GLP-1RA (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc.) was evaluated through 1-4 years of follow-up, and the effects of long-term treatment on blood glucose and body fat of patients.

Key Dates

Start date
Aug 1, 2023
Status verified
Jun 2023
Primary completion
Jan 1, 2024
Completion
Jan 1, 2024

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Dulaglutide
    Once a week, subcutaneous injection
  • Active Comparator: semaglutide
    Once a week, subcutaneous injection
  • Active Comparator: Loseenatide
    Once a week, subcutaneous injection
  • Active Comparator: tirzepatide
    Once a week, subcutaneous injection
  • Active Comparator: elbenatide
    Once a week, subcutaneous injection
  • Active Comparator: original treatment
    Once a week, subcutaneous injection
  • Placebo Comparator: placebo
    The patients will be treated according to the original protocol

Primary Outcome Measure

Effects of different GLP-1 on blood glucose [ Time Frame: 1,2,3,4 year ]

Central Contacts

Related Studies